135 related articles for article (PubMed ID: 24470499)
1. Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response.
Bartholomaeus P; Semmler LY; Bukur T; Boisguerin V; Römer PS; Tabares P; Chuvpilo S; Tyrsin DY; Matskevich A; Hengel H; Castle J; Hünig T; Kalinke U
J Immunol; 2014 Mar; 192(5):2091-8. PubMed ID: 24470499
[TBL] [Abstract][Full Text] [Related]
2. Antibody C region influences TGN1412-like functional activity in vitro.
Ball C; Fox B; Hufton S; Sharp G; Poole S; Stebbings R; Eastwood D; Findlay L; Parren PW; Thorpe R; Bristow A; Thorpe SJ
J Immunol; 2012 Dec; 189(12):5831-40. PubMed ID: 23150712
[TBL] [Abstract][Full Text] [Related]
3. Human Fcγ receptors compete for TGN1412 binding that determines the antibody's effector function.
Dudek S; Weißmüller S; Anzaghe M; Miller L; Sterr S; Hoffmann K; Hengel H; Waibler Z
Eur J Immunol; 2019 Jul; 49(7):1117-1126. PubMed ID: 31002172
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412.
Hussain K; Hargreaves CE; Roghanian A; Oldham RJ; Chan HT; Mockridge CI; Chowdhury F; Frendéus B; Harper KS; Strefford JC; Cragg MS; Glennie MJ; Williams AP; French RR
Blood; 2015 Jan; 125(1):102-10. PubMed ID: 25395427
[TBL] [Abstract][Full Text] [Related]
5. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
Römer PS; Berr S; Avota E; Na SY; Battaglia M; ten Berge I; Einsele H; Hünig T
Blood; 2011 Dec; 118(26):6772-82. PubMed ID: 21931118
[TBL] [Abstract][Full Text] [Related]
6. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture.
Findlay L; Sharp G; Fox B; Ball C; Robinson CJ; Bird C; Stebbings R; Eastwood D; Wadhwa M; Poole S; Thorpe R; Thorpe SJ
Cytokine; 2011 Jul; 55(1):141-51. PubMed ID: 21493088
[TBL] [Abstract][Full Text] [Related]
7. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
[TBL] [Abstract][Full Text] [Related]
8. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.
Wolf B; Morgan H; Krieg J; Gani Z; Milicov A; Warncke M; Brennan F; Jones S; Sims J; Kiessling A
Cytokine; 2012 Dec; 60(3):828-37. PubMed ID: 22986013
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.
Veri MC; Gorlatov S; Li H; Burke S; Johnson S; Stavenhagen J; Stein KE; Bonvini E; Koenig S
Immunology; 2007 Jul; 121(3):392-404. PubMed ID: 17386079
[TBL] [Abstract][Full Text] [Related]
10. ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation.
Weissmüller S; Semmler LY; Kalinke U; Christians S; Müller-Berghaus J; Waibler Z
Blood; 2012 Jun; 119(26):6268-77. PubMed ID: 22577174
[TBL] [Abstract][Full Text] [Related]
11. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies.
Bailey L; Moreno L; Manigold T; Krasniqi S; Kropshofer H; Hinton H; Singer T; Suter L; Hansel TT; Mitchell JA
J Pharmacol Toxicol Methods; 2013; 68(2):231-239. PubMed ID: 23280407
[TBL] [Abstract][Full Text] [Related]
12. Important roles of CD32 in promoting suppression of IL-4 induced immune responses by a novel anti-IL-4Rα therapeutic antibody.
Zhao J; Jiang L; Deng L; Xu W; Cao Y; Chen C; Yang Y; Wu H; Huang Y; Zhu Z; Huang H
MAbs; 2019 Jul; 11(5):837-847. PubMed ID: 30950681
[TBL] [Abstract][Full Text] [Related]
13. Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity.
Chenoweth AM; Esparon S; Wines BD; Schuurman J; Labrijn AF; Hogarth PM
Immunol Cell Biol; 2023 Aug; 101(7):657-662. PubMed ID: 36997299
[TBL] [Abstract][Full Text] [Related]
14. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies.
Dhir V; Fort M; Mahmood A; Higbee R; Warren W; Narayanan P; Wittman V
J Immunotoxicol; 2012; 9(1):34-42. PubMed ID: 22074378
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner.
Vos AC; Wildenberg ME; Duijvestein M; Verhaar AP; van den Brink GR; Hommes DW
Gastroenterology; 2011 Jan; 140(1):221-30. PubMed ID: 20955706
[TBL] [Abstract][Full Text] [Related]
16. Highly sensitive
Ito S; Miwa K; Hattori C; Aida T; Tsuchiya Y; Mori K
J Immunotoxicol; 2021 Dec; 18(1):136-143. PubMed ID: 34644231
[TBL] [Abstract][Full Text] [Related]
17. CD32 Ligation Promotes the Activation of CD4
Holgado MP; Sananez I; Raiden S; Geffner JR; Arruvito L
Front Immunol; 2018; 9():2814. PubMed ID: 30555482
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models.
Yan H; Bhagwat B; Sanden D; Willingham A; Tan A; Knapton AD; Weaver JL; Howard KE
Toxicol Appl Pharmacol; 2019 Jun; 372():57-69. PubMed ID: 30914376
[TBL] [Abstract][Full Text] [Related]
19. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
20. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3.
Parren PW; Warmerdam PA; Boeije LC; Capel PJ; van de Winkel JG; Aarden LA
J Immunol; 1992 Feb; 148(3):695-701. PubMed ID: 1530954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
